[Pubmed] Pathogenic Autoantibodies in Myasthenia Gravis

[RSS-Bot]

Brain Nerve. 2023 Jul;75(7):831-835. doi: 10.11477/mf.1416202428.

ABSTRACT

Myasthenia gravis (MG) is a representative autoantibody-mediated immune disorder in whose pathogenesis autoantibodies play a central role. Acetylcholine receptor (AChR), muscle-specific tyrosine kinase (MuSK), and LDL receptor-related protein 4 (Lrp4) antibodies are known to be pathogenic autoantibodies for MG. However, whether the Lrp4 antibody is pathogenic to MG is controversial because of its lack of disease specificity. This review focuses on the targets of these autoantibodies at the neuromuscular junction; the clinical significance of antibody positivity; and the differences in clinical presentation, treatment, and prognosis according to pathogenic autoantibodies.

PMID:37431073 | DOI:10.11477/mf.1416202428


Source: https://pubmed.ncbi.nlm.nih.gov/3743107 ... t6+86293ac